1. Home
  2. INTS vs PMN Comparison

INTS vs PMN Comparison

Compare INTS & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • PMN
  • Stock Information
  • Founded
  • INTS 2012
  • PMN 2004
  • Country
  • INTS United States
  • PMN Canada
  • Employees
  • INTS N/A
  • PMN N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • INTS Health Care
  • PMN Health Care
  • Exchange
  • INTS Nasdaq
  • PMN Nasdaq
  • Market Cap
  • INTS 33.4M
  • PMN 29.8M
  • IPO Year
  • INTS 2023
  • PMN N/A
  • Fundamental
  • Price
  • INTS $2.11
  • PMN $0.95
  • Analyst Decision
  • INTS Strong Buy
  • PMN
  • Analyst Count
  • INTS 3
  • PMN 0
  • Target Price
  • INTS $8.50
  • PMN N/A
  • AVG Volume (30 Days)
  • INTS 28.4K
  • PMN 43.9K
  • Earning Date
  • INTS 03-13-2025
  • PMN 03-31-2025
  • Dividend Yield
  • INTS N/A
  • PMN N/A
  • EPS Growth
  • INTS N/A
  • PMN N/A
  • EPS
  • INTS N/A
  • PMN N/A
  • Revenue
  • INTS N/A
  • PMN N/A
  • Revenue This Year
  • INTS N/A
  • PMN N/A
  • Revenue Next Year
  • INTS N/A
  • PMN N/A
  • P/E Ratio
  • INTS N/A
  • PMN N/A
  • Revenue Growth
  • INTS N/A
  • PMN N/A
  • 52 Week Low
  • INTS $1.50
  • PMN $0.87
  • 52 Week High
  • INTS $5.94
  • PMN $2.61
  • Technical
  • Relative Strength Index (RSI)
  • INTS 41.98
  • PMN 52.16
  • Support Level
  • INTS $1.84
  • PMN $0.88
  • Resistance Level
  • INTS $2.53
  • PMN $1.03
  • Average True Range (ATR)
  • INTS 0.32
  • PMN 0.06
  • MACD
  • INTS -0.02
  • PMN 0.00
  • Stochastic Oscillator
  • INTS 37.50
  • PMN 46.67

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: